BACKGROUND Multiple myeloma (MM) is a plasma cell disorder characterized by the infiltration of clonal plasma cells in the bone marrow and the detection of a monoclonal immunoglobulin in serum and/or urine. Renal failure, anemia, hypercalcemia, and the presence of bone lesions are the hallmarks of the disease. The study aimed to evaluate the clinical, hematological, radiological, and immunophenotypic features of MM patients and to identify prognostic factors influencing survival outcomes. This cohort study included 77 newly diagnosed, untreated MM patients. Their clinical presentation, laboratory data, imaging results, and the expression of flow cytometry markers were analyzed in correlation with the 1-year overall survival (OS). The mean age was 59.29 ± 12.1 years, bone pain was the most common symptom (81.8%), and anemia was observed in 87% of patients. Radiologically, lytic lesions were present in 70.1% of cases, with 33.8% having pathological fractures. Flow cytometry revealed universal expression of CD319 (100%) and high expression of CD56 (98.7%). CD117 positivity was significantly associated with shorter OS ( P = 0.029), and CD28 showed a tendency toward poorer prognosis ( P = 0.054). Other markers, such as CD44 and CD49e, did not show significant prognostic associations. MM may manifest at an earlier age in specific populations. The most significant features were anemia, bone lesions, and renal dysfunction. Lower hemoglobin levels, higher blood urea and serum creatinine, along with a lower glomerular filtration rate, hyperuricemia, and hypoalbuminemia, contribute to poorer outcomes, as the expression of CD117 has an inverse prognostic outcome.
